Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Pfizer

In a pandemic milestone, the NIH ends guidance on COVID treatment

The National Institutes of Health is sunsetting its influential COVID-19 treatment guidelines, used by millions of doctors to guide care during the pandemic.

WEKU

COVID patients can't get Paxlovid

The price is one reason Paxlovid is not reaching those who need it most

Salon

Why covid patients who could most benefit from paxlovid still aren’t getting it

During the pandemic, the federal government offered Americans a 5-day course of Paxlovid, the antiviral drug that lessens COVID-19 symptoms. But now that Pfizer is charging for it, confusion over insurance coverage, price, has made patients wary.

The Texas Tribune

From analysis to the latest developments in health,
read the most diverse news in one place.

Covid vaccines cut risk of virus-related heart failure and blood clots, study finds

Researchers say jabs substantially reduce for up to a year the chances of serious cardiovascular complications

The Guardian - UK

Does Anonymity Defeat Associational Standing?

The Second Circuit divides over whether an association must identify an injured member by name for the purposes of Article III. (Updated)

Reason

U.S. must stop syphilis killing babies

The government isn’t doing much to prevent shortages of the only drug that treats syphilis during pregnancy

Salon

Cathie Wood sells almost 135,000 shares of a top crypto stock

Bitcoin has jumped 52% year to date and is trading at record levels.

The Street

Read news from The Economist, FT, and more,
with one subscription

Should You Buy These 2 Dividend Stocks Yielding More Than 5% Right Now?

There are other reasons to consider buying a dividend stock besides the high yield. Here's a closer look at two stocks that offer yields over 5% right now.

Barchart

BridgeBio Dives After Inking A $310 Million Deal With Bayer For Its Lead Drug

Bayer snagged commercial rights to BridgeBio's lead asset, acoramidis, in Europe for $310 million. But BridgeBio stock tumbled Monday.

Investors Business Daily

2 Cheap Dividend Stocks to Buy This March and Hold for the Long Term

While the S&P 500 Index's dividend yield is just about half of its long-term averages, Ford and Pfizer are two dividend-paying stocks that offer healthy yields. Plus, their cheap valuations mean that there is a reasonable probability of upside over the next couple of years.

Barchart

50 Top Companies By Market Capitalization: The Global Giants

These companies are the ones that dominate the market and will continue to do so should factors remain constant.

International Business Times

Surge in syphilis cases drives some doctors to ration penicillin

The drug is the go-to treatment for syphilis and the only one recommended for pregnant people. But a shortage of the injectable drug has prompted some public health agencies to ration it.

WEKU

A Better Way To Fight Future Pandemics

Four years after the emergence of Covid-19, the conversation in global public health has moved on from dealing with an immediate crisis to how we can best prepare for the next pandemic.

International Business Times

Large COVID-19 vaccine study finds risks

Any pharmaceutical has risk of side effects, but a COVID infection is far more dangerous than the vaccines

Salon

Get all your
news in one place.

100’s of premium titles.
One news app.

The Guardian - AU

Two very rare Covid vaccine side-effects detected in global study of 99 million

Results confirm how uncommon known complications are as researchers confirm benefits from vaccines still ‘vastly outweigh the risks’

Investors Business Daily

Moderna Surges 14% After Covid Vaccine-Maker Surprises With Fourth-Quarter Profit

Moderna stock surged Thursday after the firm beat quarterly expectations, including turning around a surprise profit.

StockNews.com

Pfizer (PFE) vs. Johnson & Johnson (JNJ) - Analyzing Pharma Stocks for Upside Potential

The pharmaceutical industry is expected to witness robust growth over the coming years due to growing healthcare needs and advancements in technology. Given this positive backdrop, let’s analyze the upside potential of pharma stocks Pfizer (PFE) and Johnson & Johnson (JNJ).

Barchart

Pfizer Stock 2025 Forecast: Will PFE Go Up Long Term?

Pfizer stock is trading at price levels last seen in 2016. The 2025 forecast for PFE stock looks positive, though, and it should go up over the medium to long term.

Get all your
news in one place.

100’s of premium titles.
One news app.

Top News

Pfizer Settles M Lipitor Antitrust Lawsuit

Read about Pfizer's settlement in the Lipitor antitrust lawsuit, where they have agreed to pay million to resolve the case. Stay informed with our late...

The Guardian - UK

Breaking Through: My Life in Science by Katalin Karikó review – real-life lessons in chemistry

This vivid account of the Hungarian biochemist who endured decades of derision before pioneering Pfizer’s Covid vaccine is a tribute to her tenacity and self-belief

Investors Business Daily

Pfizer Reports Surprise Profit Despite Continued Covid Sales Downfall

Pfizer stock sank early Tuesday after the pharma giant unexpectedly reported a fourth-quarter profit despite missing sales expectations.

Investors Business Daily

Dow Jones Falls After Key Economic Data; Alphabet, AMD, Microsoft To Report

The Dow Jones Industrial Average dropped Tuesday on key economic data. Alphabet, Microsoft and AMD will report earnings late.

StockNews.com

Pfizer (PFE): Pre-Earnings Strategies

Pfizer (PFE) is facing hurdles due to weakened demand for its products and pipeline diversification challenges. Nevertheless, the company exhibits long-term potential through strategic acquisitions. Given this scenario, what course of action should be considered ahead of the upcoming earnings release? Read more to find out.

Medical Daily

More Than 150 Infants, Pregnant Women Given Incorrect RSV Vaccine, CDC Says

According to reports, there have been 25 cases of accidental administration of Pfizer (Abrsyvo) or GSK (Arexvy) RSV vaccines to children below two and 128 cases of mistaken administration of the GSK RSV vaccine (Arexvy) to pregnant women.

Investors Business Daily

Ex-Pfizer Employee Netted $270,000 In Illicit Profits Tied To Paxlovid Results

A former Pfizer employee profited to the tune of $270,000 in an insider-trading scheme tied to Covid antiviral test results.

1 … 8 9 10 11

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.